Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?

Autor: El Chaer F; Department of Medicine, Division of Hematology and Oncology, University of Virginia, Charlottesville, VA, USA., Perissinotti AJ; Department of Clinical Pharmacy, Michigan Medicine and the University of Michigan College of Pharmacy, Ann Arbor, MI, USA., Loghavi S; Department of Leukemia and Hematopathology, The University of Texas, MD Anderson, Houston, TX, USA., Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA. amer.zeidan@yale.edu.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2024 Nov 05. Date of Electronic Publication: 2024 Nov 05.
DOI: 10.1038/s41375-024-02458-6
Abstrakt: The use of measurable residual disease (MRD) as a biomarker for prognostication, risk stratification, and therapeutic decision-making in acute myeloid leukemia (AML) is gaining prominence. MRD monitoring for NPM1-mutated and core-binding factor AML using PCR techniques is well-established for assessing disease after intensive chemotherapy. AML with persistent FLT3-ITD MRD post-intensive chemotherapy and pre-allogeneic hematopoietic cell transplantation (pre-allo-HCT) is associated with an increased risk of relapse and lower survival. Pre-allo-HCT MRD is an independent risk factor for post-allo-HCT outcomes, including relapse and death. Therefore, preemptive interventions on the natural history of MRD positivity are an active area of research beyond its initial prognostic function. Targeting MRD in AML with innovative treatment strategies can improve patient outcomes.
(© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: